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Abstract Persistent reservoirs remain the major obstacles to achieve an HIV-1 cure. Prolonged
early antiretroviral therapy (ART) may reduce the extent of reservoirs and allow for virological
control after ART discontinuation. We compared HIV-1 reservoirs in a cross-sectional study using
polymerase chain reaction-based techniques in blood and tissue of early-treated seroconverters,
late-treated patients, ART-naı¨ve seroconverters, and long-term non-progressors (LTNPs) who have
spontaneous virological control without treatment. A decade of early ART reduced the total and
integrated HIV-1 DNA levels compared with later treatment initiation, but not reaching the low
levels found in LTNPs. Total HIV-1 DNA in rectal biopsies did not differ between cohorts.
Importantly, lower viral transcription (HIV-1 unspliced RNA) and enhanced immune preservation
(CD4/CD8), reminiscent of LTNPs, were found in early compared to late-treated patients. This
suggests that early treatment is associated with some immunovirological features of LTNPs that
may improve the outcome of future interventions aimed at a functional cure.
DOI: 10.7554/eLife.09115.001
Introduction
A reservoir of long-lived latently HIV-1 infected cells is established early in the course of the infec-
tion. It persists despite suppressed viremia in patients undergoing effective antiretroviral therapy
(ART) and fuels viral rebound upon treatment discontinuation (Wong et al., 1997; Finzi et al., 1997;
Chun et al., 1997; Finzi et al., 1999; Fernandez et al., 2005; Alexaki et al., 2008). Not only is this
reservoir present in blood, but also in tissues such as lymphoid organs, the gut and potentially the
central nervous system (Chun et al., 2008; Sturdevant et al., 2015; Bednar et al., 2015).
The mechanisms underlying HIV-1 persistence have not been fully elucidated. Although an initial
decay of these reservoirs is observed after ART intervention, it is assumed that replenishment may
occur through clonal proliferation of infected CD4 T cells during ART (Chomont et al., 2009;
Josefsson et al., 2013; Maldarelli et al., 2014; Murray et al., 2014) or through residual virus pro-
duction despite suppressive ART (Chun et al., 2008; Buzon et al., 2010; Hatano et al., 2013a)
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possibly in sanctuary sites where ART penetration is suboptimal (Yukl et al., 2010; Fletcher et al.,
2014).
Low levels of viral reservoirs have been associated with an absence of viral rebound after treat-
ment discontinuation in several case reports and the Visconti cohort, suggesting the possibility of
post-treatment virological control even in the presence of viral reservoirs (Salgado et al., 2011;
Van Gulck et al., 2012; Saez-Cirion et al., 2013; Kinloch-de Loes et al., personal communication).
Achieving such a long-term control of HIV-1 replication in the absence of ART is widely defined as a
functional cure (Saag and Deeks, 2010; Fauci and Folkers, 2009). A low saturation of viral reser-
voirs facilitated by early treatment initiation might be a necessary condition, although not in itself
sufficient for post-treatment virological control (Saez-Cirion et al., 2013; Van Gulck et al., 2012).
Recent evidence indicates that the interplay between virological and immunological parameters is
likely to be fundamental to achieve this goal (Cellerai et al., 2011). A sustained remission from vire-
mia rebound seems a more realistic prospect in terms of HIV-1 cure research in the short term
(Katlama et al., 2013).
Early treatment initiation with ART will likely become the standard clinical practice in HIV care.
This is supported by the recent outcome of the first large-scale international ’Strategic Timing of
AntiRetroviral Treatment’ (START) study, showing a considerably lower risk of developing AIDS and
other serious conditions when compared to later treatment initiation (INSIGHT START Study Group,
2015). Interestingly, early treatment initiation during HIV-1 seroconversion is also the most effective
intervention to limit the extent of viral reservoirs (Ananworanich et al., 2012; Hoen et al., 2007;
Hocqueloux et al., 2013; Ananworanich et al., 2015). Very low or even undetectable HIV-1 DNA
has been described when treatment is initiated during the very early stages of primary HIV-1 infec-
tion (PHI) (Ananworanich et al., 2012; Laanani et al., 2015). In addition, a lower level of HIV-1 tran-
scription has been described in ART-treated patients who initiated treatment during seroconvertion
(Schmid et al., 2010).
eLife digest Many people with HIV infections are able to live relatively normal lives thanks to
major advances in drug therapies. A cure, however, remains elusive. One reason for this is that the
virus can hide in certain types of human cells, where it is protected from the immune system and the
effects of “antiretroviral” drugs. This creates reservoirs of virus particles in the body that can quickly
multiply and spread if treatment stops.
Some people who become infected with HIV are able to contain the virus without the help of
drug treatments. These individuals – known as long-term non-progressors – do not become ill and
only have low numbers of HIV particles in reservoirs. People who receive treatment early in the
course of an HIV infection also have fewer viruses in reservoirs and are less likely to develop severe
illness. Therefore, it might be possible to develop a “functional” cure that may not completely
eliminate the virus from the body, but would prevent illness and allow the individuals to eventually
stop taking antiretroviral drugs.
Now, Malatinkova, De Spiegelaere et al. studied samples from 84 patients with HIV-1 to find how
much effect an early start to treatment has on the amount of the virus in reservoirs. People who
started treatment soon after infection had lower levels of HIV-1 in their blood than people who
started treatment later (even after 10 years of treatment). However, patients that started treatment
early had higher levels of HIV-1 in the blood than the patients who were long-term non-progressors.
All the patients had similar levels of HIV-1 in tissue samples taken from the rectum, regardless of
when they started treatment.
The experiments suggest that HIV-1 reservoirs form very soon after infection. Malatinkova, De
Spiegelaere et al. found that in addition to reducing reservoirs of HIV-1, an early start to drug
treatment reduced the ability of the virus to make copies of its genetic code. People who started
treatment earlier also had healthier immune cells. Together, the experiments support the benefits of
starting drug treatments as soon as possible after a person is infected with HIV-1. It is important to
further characterize thoroughly the viral reservoir in patients with limited HIV-1 reservoirs and to look
for other immune factors involved in virus control, in the search for a functional cure of HIV.
DOI: 10.7554/eLife.09115.002
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Elite controllers and long-term non-progressors (LTNPs) represent an important group as a com-
parator. These HIV-1 infected individuals display low or undetectable blood reservoirs, and are able
to control viremia over the long-term with limited CD4 T cell loss in the absence of treatment. Con-
sequently, LTNPs have been extensively studied in an attempt to unravel the underlying mechanisms
of spontaneous virological control (Autran et al., 2011; Deeks and Walker, 2007). Although their
viral reservoirs have been shown to be low, replication-competent viruses can still be found in these
individuals (Blankson et al., 2007; Buzon et al., 2014). LTNPs display strong HIV-1-specific T cells
responses with polyfunctionality, thereby suggesting a role of T cell immunity in viremia control
(Cellerai et al., 2011).
In the present study, we have assessed whether undetectable or low levels of reservoirs in blood
and tissue could be achieved with very prolonged therapy initiated at PHI or during chronic infection
using newly-developed polymerase chain reaction (PCR)-based virological assays for in-depth mea-
surement of the size of the HIV-1 reservoir in blood (total and integrated HIV-1 DNA) and its dynam-
ics (episomal 2-long terminal repeat (LTR) circles and cell-associated unspliced RNA [usRNA]) as well
as total HIV-1 DNA burden in the rectal mucosa. These patients were compared to LTNPs and to
untreated seroconverters.
We have analyzed whether 1) a decade of ART or an LTNP status was associated with the
absence of detectable HIV-1 DNA in the blood and rectal mucosa; 2) long-term treated seroconvert-
ers could reach levels of virological reservoirs, residual replication, and transcription comparable to
those of LTNPs; 3) a similar period of aviremia with ART initiation during the chronic phase of HIV-1
infection could achieve levels of reservoirs, residual replication, and transcription comparable to
long-term treated seroconverters; 4) immune reconstitution, as measured by CD4/CD8 ratio, was
enhanced with early treatment intervention; and 5) a correlation was present between the various
virological and immunological parameters used in this study.
Results
Study participant characteristics
Eighty-four patients were included in this cross-sectional study from four different cohorts: patients
who had undergone a decade of successful ART, initiated either during seroconversion (SRCV on
ART; n = 25) or during the chronic phase of the infection (Chronic ART, n = 32), LTNPs (n = 17), and
recently infected ART-naı¨ve seroconverters (Recent SRCV; n = 10) (Figure 1; Table 1). The CD4 nadir
was significantly different between each of the cohorts (p < 0.001) except between SRCV on ART
and Recent SRCV (p = 0.623). The patients were sampled at a single time point (blood and rectal
biopsies) to perform PCR-based assays and characterize viral reservoirs and its dynamics (total and
integrated HIV-1 DNA, 2-LTR circles, and HIV-1 usRNA).
Total and integrated HIV-1 DNA in blood is reduced after a decade of
ART with early treatment initiation, but does not reach the low levels
found in LTNPs
Total HIV-1 DNA represents the most commonly used virological marker for the assessment of the
size of the proviral HIV-1 reservoir and is predictive of viral rebound when tested at the time of treat-
ment interruption in early-treated patients (Williams et al., 2014). We have assessed the impact of
the temporal treatment initiation (during early versus chronic infection) in the context of very pro-
longed ART treatment (e.g. a decade) on this marker and compared results to those of LTNPs and
acute seroconverters before ART initiation to assess the size of HIV-1 DNA using digital PCR.
All patient cohorts had detectable levels of total HIV-1 DNA in peripheral blood mononuclear
cells (PBMCs). Differences in the reservoir size in terms of total HIV-1 DNA were observed between
patient cohorts. Median total HIV-1 DNA was: 92 (interquartile range (IQR): 9.8–127.7), 48 (IQR: 5.4–
56.5), 137 (IQR: 8.6–219.2) and 1901.3 (IQR: 602.4–4786.9) copies (c)/106 PBMCs in SRCV on ART,
LTNPs, Chronic ART, and Recent SRCV, respectively. Lower total HIV-1 DNA was detected in the
SRCV on ART compared to the Chronic ART cohort (p = 0.041; Figure 2A). The LTNP cohort
showed the lowest total HIV-1 DNA levels when compared to SRCV on ART (p = 0.015) and other
patient cohorts (p < 0.001; Figure 2A). These results demonstrate that, the total HIV-1 DNA remains
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Figure 1. Patient cohorts in the cross-sectional study. SRCV on antiretroviral therapy (ART): patient cohort with ART initiated at the time of HIV-1
seroconversion; LTNP: long-term non-progressors; Chronic ART: patients with ART initiated during the chronic phase of HIV-1 infection; Recent SRCV:
recent ART-naı¨ve seroconverters. In total, 84 patients were included in this study, 25 in SRCV on ART, 17 LTNPs, 32 Chronic ART patients, and 10
Recent SRCV. Blue arrows represent time of sampling. PHI: primary HIV-1 infection.
DOI: 10.7554/eLife.09115.003
Table 1. Clinical and laboratory characteristics of the four patient cohorts.
Value for cohort*
SRCV on ART LTNP Chronic ART Recent SRCV
n = 25 n = 17 n = 32 n = 10
Clinical characteristics
Age (years) 44 (34–53) 49 (31–51) 48 (31–53) 39 (30–46)
Number of females (%) 0 (0) 7 (41.2) 5 (15.6) 1 (10)
Total ART duration (years) 10.8 (4.2–11.9) 0 9.8 (4.9–14.7) 0
Viremia zenith (log10HIV-1 c/ml) 5.5 (2.4–5.9) 2.5 (1.6–2.8) 4.9 (1.9–5.5) 6.2 (5.2–6.4)
CD4 count, nadir (cells/mm3) 390 (107–466) 624 (507–693) 155 (0–266) 440 (284–495)
CD4 count at sampling (cells/mm3) 714 (476–977) 793 (414–1010) 624.5 (172–889) 440 (284–604)
CD4/CD8 ratio 1.10 (0.52–1.35) 0.91 (0.36–1.47) 0.74 (0.23–0.93) 0.62 (0.36–0.94)
Virological markers
Total HIV-1 DNA (c/106 PBMCs) 92 (9.8–127.7) 48 (5.4–56.5) 137 (8.6–219.2) 1901.3 (602.4–4786.9)
Integrated HIV-1 DNA (c/106 PBMCs) 211.3 (0–589.3) 28.2 (0–158.4) 586.7 (131.6–918.2) 1802.7 (367.9–5890.6)
HIV-1 usRNA (c/106 PBMCs) 1.6 (0–3.7) 0.4 (0–3.51) 6.1 (0–10.1) 15.5 (0.9–100.6)
2-LTR circles (c/106 PBMCs) 2.1 (0–4.3) 0.8 (0–2.7) 1.3 (0–2.2) 13.3 (5.1–21.6)
Total HIV-1 DNA (c/106 cells) in rectal biopsies 27.2 (22.2–61.7) 21.3 (16.7–34.5) 35.1 (16–77.5)
*Values are reported as median (IQR); c: copies; PBMCs: peripheral blood mononuclear cells; usRNA: unspliced RNA; ART: antiretroviral therapy; SRCV
on ART: early treated seroconverters; LTNP: long-term non-progressors; Chronic ART: late treated patients during chronic HIV-1 infection; Recent
SRCV: acute ART-naı¨ve seroconverters; LTR: Long terminal repeat.
DOI: 10.7554/eLife.09115.004
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detectable in all patients even in the setting of effective early and prolonged ART, although at lower
levels than in patients with later ART initiation, but not reaching the levels found in LTNPs.
In addition to total HIV-1 DNA levels, we also measured integrated HIV-1 DNA levels. This marker
is not biased by the presence of variable quantities of unintegrated HIV-1 DNA produced after
reverse transcription of newly infecting HIV-1 or dead-end DNA products of failed integration such
as 1- and 2-LTR circles. Some authors have suggested that integrated HIV-1 DNA represents a better
surrogate marker of viral burden, especially in patients off ART in whom HIV-1 replication might be
ongoing (Graf et al., 2011).
Median integrated HIV-1 DNA levels were: 211.3 (IQR: 0–589.3), 28.2 (IQR: 0–158.4), 586.7 (IQR:
131.6–918.2), and 1802.7 (IQR: 367.9–5890.6) c/106 PBMCs for SRCV on ART, LTNPs, Chronic ART,
and Recent SRCV, respectively. A lower level of integrated HIV-1 DNA was found in SRCV on ART
compared to the Chronic ART cohort (p = 0.003) and in LTNPs compared to both the SRCV on ART
(p = 0.021) and Chronic ART cohorts (p < 0.001; Figure 2B). These results confirm the low levels of
integrated DNA found in LTNPs as described previously (Graf et al., 2011). Interestingly, levels of
integrated HIV-1 DNA were not significantly different between the ART-naı¨ve Recent SRCV and the
Chronic ART cohort (p = 0.104). The Recent SRCV cohort displayed higher integrated HIV-1 DNA
levels compared to SRCV on ART (p = 0.006) and LTNPs (p = 0.002; Figure 2B).
Of note, the absolute values derived from total and integrated HIV-1 DNA measurements in this
study cannot be directly compared with each other. This is due to the difference in quantification
methods, the absolute quantification of integrated HIV-1 DNA being corrected by using an integra-
tion standard as calibrator as previously described (Liszewski et al., 2009; De Spiegelaere et al.,
2014). This calibrator does not alter the relative differences of integrated HIV-1 DNA between
patient samples, but may bias the absolute quantitative outcome. In contrast, total HIV-1 DNA is
reported by direct absolute quantification and represents a better estimate of the amount of HIV-1
DNA c/106 cells present in patients.
Due to the lower limit of detection compared to that of the total HIV-1 DNA assay, integrated
HIV-1 DNA was undetectable in 12 patients; 5 were SRCV on ART, 6 LTNPs, and 1 Recent SRCV.
Levels of episomal 2-LTR circles in blood are low in ART-treated
patients and LTNPs but high in recent ART-naı¨ve seroconverters
Residual viral replication is one of the likely mechanisms through which the viral reservoir is replen-
ished, even with effective ART (Hong and Mellors, 2015). Markers that reflect such a phenomenon
provide insight into the reservoir dynamics. Episomal 2-LTR circles can be used as a marker of viral
replication and have been shown to be labile end-products of failed proviral integrations
(Sharkey et al., 2005; 2011). They are likely to be particularly elevated in acutely infected patients
Figure 2. Total HIV-1 DNA (A) and integrated HIV-1 DNA (B) in four patient cohorts. Data is shown as log10 copies/million (c/M) PBMCs and significant
p-values are indicated by *. Differences between the cohorts were determined by Wilcoxon Signed Rank test.
DOI: 10.7554/eLife.09115.005
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because of the intense level of viral replication. Median levels of 2-LTR circles in the various cohorts
were: 2.1 (IQR: 0–4.3), 0.77 (IQR: 0–2.7), 1.3 (IQR: 0–2.2) and 13.3 (IQR: 5.1–21.6) c/106 PBMCs in
SRCV on ART, LTNPs, Chronic ART, and Recent SRCV, respectively. As expected, 2-LTR levels were
significantly higher in the Recent SCRV compared to the other cohorts (p  0.002; Figure 3A), but
did not differ between SRCV on ART and Chronic ART (p = 0.259) or LTNPs (p = 0.595) or between
the Chronic ART and LTNP cohorts (p = 0.743;Figure 3A). Of note, 2-LTR circles were undetectable
in a number of patients. They were detected in 17/25 (68%) of SRCV on ART, 13/17 (76%) of LTNPs,
25/32 (78%) of late-treated patients and in all recent ART-naı¨ve seroconverters 10/10 (100%). The
absence of detection in about one-quarter of patients on ART in contrast to the Recent SRCV cohort
suggests that residual replication is substantially halted with ART.
Cell-associated HIV-1 usRNA levels in blood are lower in early-treated
seroconverters than in late-treated patients but not different compared
to LTNPs
Levels of cell-associated HIV-1 usRNA are associated with recent HIV-1 transcriptional activity and
indicate an active proviral reservoir (Pasternak et al., 2013). Median levels were: 1.6 (IQR: 0–3.7),
0.4 (IQR: 0–3.5), 6.1 (IQR: 0–10.1) and 15.5 (IQR: 1–100.6) c/106 PBMCs in SRCV on ART, LTNPs,
Chronic ART, and Recent SRCV, respectively. The patients with the highest levels of HIV-1 usRNA
were found in the Recent SRCV cohort, indicating that this cohort is not similar to the others, but
Figure 3. 2-LTR circles (A), cell-associated HIV-1 usRNA (B) and CD4/CD8 ratio (C) in four patient cohorts. Total HIV-1 DNA in rectal biopsies (D) in
three patient cohorts (SRCV on ART, LTNP, and Chronic ART). Data is shown as log10 copies/million (c/M) PBMCs (A,B), ratio (C) or log10 c/M cells in
rectal biopsies (D) and significant p-values are indicated by *. Differences between the cohorts were determined by Wilcoxon Signed Rank test.
DOI: 10.7554/eLife.09115.006
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this study was underpowered to reach statistical significance between the Recent SRCV and the
other cohorts. Of note, HIV-1 usRNA was not detected in 8/84 samples (10%, two samples in each
patient cohort). Three samples (one in SRCV on ART and two in Chronic ART) were excluded from
the final analysis due to missing values for the reference genes. Higher levels of HIV-1 usRNA were
detected in the Chronic ART cohort compared to the SRCV on ART (p = 0.007) and LTNPs (p =
0.027; Figure 3B). The SRCV on ART cohort was not significantly different from LTNPs based on
HIV-1 usRNA levels (p = 0.615; Figure 3B).
A higher CD4/CD8 ratio is present in early-treated seroconverters and
LTNPs compared to late-treated patients
Not only have we used the CD4/CD8 ratio as a measure of immune preservation/reconstitution in
terms of T cell count but also as an indirect marker of residual immune activation as shown recently
(Serrano-Villar et al., 2014). The CD4/CD8 ratio was higher in SRCV on ART (median = 1.10, IQR:
0.52–1.35) compared to the cohorts of Chronic ART (median = 0.74, IQR: 0.23–0.93), (p = 0.009)
and Recent SRCV (median = 0.62, IQR: 0.36–0.94), (p = 0.017), and was comparable to that of LTNPs
(median = 0.91, IQR: 0.36–1.47), (p = 0.978; Figure 3C). The LTNP cohort had a higher CD4/CD8
ratio compared to late-treated patients (p = 0.036) and Recent SRCV (p = 0.048; Figure 3C). Of
note, CD4 T cell counts at sampling did not differ significantly between the cohorts of SRCV on ART
(median = 714 cells/mm3, IQR: 476–977) and Chronic ART (median = 625 cells/mm3, IQR: 172–889),
(p = 0.066).
Total HIV-1 DNA levels in rectal biopsies are not different in early-
treated seroconverters, late-treated patients, and LTNPs
Conflicting results have been published regarding the impact of ART on the HIV-1 DNA reservoir in
the gut compartment when using rectal biopsies (Yukl et al., 2010; Chun et al., 2008; Anton et al.,
2003). It remains unclear whether HIV-1 DNA decays more substantially after a decade of ART com-
pared to a shorter intervention and whether some LTNPs may have undetectable levels in rectal
biopsies. We have measured total HIV-1 DNA in rectal biopsies from 51 patients who had consented
to sampling: 14 SRCV on ART, 8 LTNPs, and 29 Chronic ART patients. Five patients had undetect-
able total HIV-1 DNA; one SRCV on ART, one LTNP, and three Chronic ART patients. Median HIV-1
DNA levels were: 27.2 (IQR: 22.2–61.7), 21.3 (IQR: 16.7–34.5), and 35.1 (IQR: 16–77.5) c/106 cells in
SRCV on ART, LTNP, and Chronic ART, respectively. No difference was found between SRCV on
ART and Chronic ART (p = 0.604) or LTNPs (p = 0.375; Figure 3D) or between the Chronic ART
cohort and the LTNPs (p = 0.337; Figure 3D). The median number of cells assayed per patient was
125,390 (IQR: 101,308–168,156). Of note, we did not find any correlation in terms of total HIV-1
DNA levels between the blood (PBMCs) and the gut mucosa (rectal biopsies) compartments (R2 = 0,
p = 0.919; Figure 4A).
Correlation between viroimmunological markers
In order to assess whether we could observe correlations between the various viroimmunological
markers used in this study, we have performed a linear regression analysis using combined data
from the cohorts of patients on ART and LTNPs. The Recent SRCV cohort was excluded from this
analysis because of its high level of active replication, which would have biased the HIV-1 usRNA, 2-
LTR, and total HIV-1 DNA measurements. For this analysis, patient-derived samples with detectable
markers were included. This was confirmed by Spearman’s rank correlation, which includes all sam-
ples (data not shown).
We found a positive correlation between HIV-1 usRNA and both total HIV-1 DNA (R2 = 0.19, p <
0.001; Figure 4B) and integrated HIV-1 DNA (R2 = 0.18, p < 0.01; Figure 4C). Total HIV-1 DNA cor-
related with integrated HIV-1 DNA levels (R2 = 0.31, p < 0.001; Figure 4D). No correlation was
observed between 2-LTR circles and HIV-1 usRNA, total or integrated HIV-1 DNA (data not shown).
A negative correlation was found between the CD4/CD8 ratio and integrated HIV-1 DNA (R2 =
0.14, p < 0.01; Figure 4E). No correlation was found between the CD4/CD8 ratio and the other viro-
logical markers assessed (total HIV-1 DNA, 2-LTR circles and usRNA in PBMCs and total HIV-1 DNA
in rectal biopsies), (data not shown).
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Discussion
In the present study, we have shown that a decade of ART, initiated during seroconversion,
decreases the HIV-1 DNA reservoir size and viral transcription level in blood, and benefits immuno-
logical restoration in comparison to later treatment initiation of the same duration. These data sup-
port the notion that early treatment initiation at the time of seroconversion may favor post-
treatment viral control by limiting the establishment of an extended viral reservoir. However, we
have also found that seeding of the viral reservoir occurs very rapidly after acquisition of the infec-
tion and, indeed, our data show that the small total and integrated HIV-1 DNA reservoir in early
treated patients is still significantly larger despite early treatment initiation when compared to
LTNPs.
As the majority of viral reservoirs is located in tissues, we sampled rectal tissues to assess the res-
ervoir size in the gut mucosa. Our results do not show a higher total HIV-1 DNA levels in this com-
partment in both early and late ART-treated patients than in LTNPs. We did not find a correlation
Figure 4. Correlation of total HIV-1 DNA in rectal biopsies and blood (A). Correlation was assessed in 46 patients in whom total HIV-1 DNA was
detected both in the blood and rectal biopsies, representing patients from three cohorts: SRCV on antiretroviral therapy (ART), Chronic ART, and long-
term non-progressors (LTNP). Data is shown as log10 copies/million (c/M) cells in rectal biopsies and log10 c/M peripheral blood mononuclear
cells (PBMCs) in blood. Correlation of blood HIV-1 usRNA and total HIV-1 DNA (B), HIV-1 usRNA and integrated HIV-1 DNA (C), integrated HIV-1 DNA
and total HIV-1 DNA (D) and CD4/CD8 ratio and integrated HIV-1 DNA (E). Data is shown as log10 c/M PBMCs in detectable patients from three
cohorts: SRCV on ART, Chronic ART, and LTNP (B–E). To assess correlations between the markers, a linear regression was performed.
DOI: 10.7554/eLife.09115.007
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between the blood and gut reservoirs. This is in accordance with one previous study (Di Stefano
et al., 2001), but not with others (Anton et al., 2003; Avettand-Fenoel et al., 2008). A less efficient
clearance of total HIV-1 DNA in rectal tissues compared to PBMCs has previously been described
after early therapy initiation (Chun et al., 2008; Ananworanich et al., 2012). Low level cryptic HIV-1
replication may be a result of sub-optimal drug penetration in this compartment, immunological
impairment, or caused by another unknown mechanism. Our results do not confirm such a hypothe-
sis, although we have observed a non-significant trend towards a lower HIV-1 DNA level in gut in
LTNPs compared to ART-treated patients. Lower levels of total HIV-1 DNA in gut were also previ-
ously detected in elite controllers compared to ART-suppressed patients (Hatano et al., 2013b). It
remains unclear how the HIV-1 reservoir in the gut compartment might be influenced by prolonged
early therapy initiation, as we did not have longitudinal samples, and whether it may contribute to
viral rebound after therapy interruption. Furthermore, sampling the gut mucosa remains an invasive
procedure compared to blood sampling, it cannot be performed as frequently and standardization
to the exact sampling location is difficult.
Residual viral replication is a topic of intense debate in the HIV-1 cure field. Evidence is accumu-
lating that the reservoirs may consist of truly latent provirus maintained in long-lived quiescent CD4
memory T cells, seeded soon after acute infection or maintained through homeostatic proliferation
(Maldarelli et al., 2014; Wagner et al., 2014; Cohn et al., 2015). Low level residual viral replication
may also represent an important mechanism in sustaining a replication-competent viral reservoir
(Sharkey et al., 2005; 2011; 2013; Hong and Mellors, 2015). The presence of 2-LTR circles is con-
sidered indicative of viral replication and, as expected in this study, its levels were highest in recent
ART-naı¨ve seroconverters who display a high amount of ongoing replication. Yet no difference was
observed between ART-treated patients and LTNPs. This suggests that ART effectively suppresses
viral replication, regardless of the timing of treatment initiation. However, the value of 2-LTR circles
as a marker for replication remains unclear as some reports suggest that 2-LTR circles are stable and
long-lived (Brussel et al., 2003; Pierson et al., 2002). Notably, the amount of 2-LTR circles was low
in a substantial number of ART-treated patients and LTNPs and undetectable in 26% of treated
patients. Levels of 2-LTR circles did not correlate with total or integrated HIV-1 DNA or HIV-1 usRNA,
indicating that factors other than the size of the viral reservoir may determine the presence of 2-LTR
circles.
We have used cell-associated HIV-1 usRNA to reflect proviral DNA transcription. This marker may
predict the replicative-competence of the viral reservoir, and previous studies have shown a correla-
tion of usRNA levels with virological failure (Pasternak et al., 2013) and markers of immune activa-
tion in elite controllers (Hunt et al., 2011). In addition, recent trials using histone deacetylase
inhibitors to stimulate viral production in the reservoir have used HIV-1 usRNA as a marker to assess
viral transcription (Archin et al., 2012; Elliott et al., 2014; Rasmussen et al., 2014; Wei et al.
2014). An earlier report has shown that early-treated patients have lower HIV-1 usRNA compared to
late-treated patients after a short period of ART (Schmid et al., 2010). With a long-term follow-up,
Buzon et al. observed a trend towards lower levels of HIV-1 usRNA in elite controllers and early-
treated patients compared to late-treated patients (Buzon et al., 2014). Here, we can confirm that
early-treated patients have lower HIV-1 usRNA compared to patients who started therapy
with onset of chronic HIV-1 infection. This observation persists after a decade of successful ART.
The levels of HIV-1 usRNA in early-treated seroconverters were not different from those of LTNPs,
suggesting that early treatment initiation reduces viral transcriptional activity to levels reminiscent of
LTNPs, which may facilitate further intervention to control such low level of viral replication. How-
ever, it must be noted that HIV-1 usRNA levels positively correlated with those of total and inte-
grated HIV-1 DNA. This may indicate that lower levels of HIV-1 usRNA are a consequence of a
smaller pool of HIV-1 DNA reservoir rather than a low transcriptional activity. Cell-associated HIV-1
usRNA levels were shown to be very low in LTNPs, thus supporting its use as a reference parameter
in future studies aimed at an HIV-1 cure.
T cell activation often remains elevated in chronic HIV-1 infection in spite of ART and is linked to
a lower rate of CD4 T cell count recovery (Goicoechea et al., 2006) and higher mortality rates (Ser-
rano-Villar et al., 2014). Lower levels of T cell activation were shown recently in early-treated
patients within 6 months of infection with a shorter ART duration (median: 2.8 years) compared to
later ART initiation (Jain et al., 2013). Here, we show that a higher CD4/CD8 ratio is found in long-
term early-treated seroconverters with levels comparable to those observed in LTNPs, confirming
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observations from a previous study (Cellerai et al., 2011). We were also able to show that the
increased CD4/CD8 ratio was associated with a smaller integrated HIV-1 DNA reservoir, but not with
total HIV-1 DNA. These two markers should therefore be further studied for their accuracy in reflect-
ing the state of the HIV-1 reservoir in cure studies.
We have shown that the virological markers used in this study are affected by early treatment ini-
tiation. They could potentially represent predictors of a functional cure or of the time to viral
rebound after ART interruption, where treatment interruption studies are necessary to validate these
predictors. Although, the inter-patient variability of results may prevent the use of reservoir markers
on an individual basis, a longitudinal follow-up of these markers may increase the rationale for their
use in such studies. Recently, an association with time to viral rebound and HIV-1 DNA was found in
early-treated patients within the SPARTAC study of seroconverters (Williams et al., 2014), and with
integrated HIV-1 DNA in a study using pegylated Interferon alfa-2a to purge the viral reservoir
(Azzoni et al., 2013). Hence, future studies should emphasize the longitudinal profiling of HIV-1 res-
ervoir markers to validate their use in cure studies.
Some of the limitations of our study include the lack of pre-treatment and longitudinal follow-up
in terms of viral reservoirs, which could provide information on their dynamics over the long-term
and indicate whether a shorter period of treatment could achieve the same reservoir levels in both
blood and tissues. The present study used PCR-based HIV-1 markers, which cannot differentiate
between the presence or absence of replicative-competent reservoirs, and we did not use ex vivo
assays such as the viral outgrowth assay (VOA) in blood, which can quantify replication-competent
proviral HIV-1 DNA, the fraction of the reservoir that matters in terms of viral eradication. Both types
of methods either overestimate or underestimate the size of the replicative-competent reservoir
(Bruner et al., 2015), and VOA remains a cumbersome and expensive assay that is not widely avail-
able and will need to be replaced by easier and cheaper assays.
In conclusion, our study provides important data on the blood HIV-1 reservoir size and dynamics
after a decade of successful treatment with ART together with gut mucosal HIV-1 DNA. Our results
support early treatment initiation in terms of achieving lower levels of viral reservoirs, when com-
pared to later treatment. The levels of HIV-1 DNA that are likely to be associated with a functional
cure remain to be determined together with other factors such as protective immunological
responses involved in virological control.
Material and methods
Patient cohorts
Eighty-four HIV-1 infected patients from four pre-defined cohorts under clinical follow-up were
enrolled into the study in two clinical centers (The Ian Charleson Day Centre, Royal Free Hospital,
London, United Kingdom and the AIDS Reference Center, Ghent University Hospital, Ghent, Bel-
gium): long-term-treated patients with ART initiated during seroconversion or chronic infection,
LTNPs, and recent ART-naı¨ve seroconverters. The first three cohorts were recruited using databases
at the clinical centers (the Royal Free Center Research Database and Ghent University Hospital Data-
base). The fourth cohort consisting of acute seroconverters was enrolled prospectively in both clini-
cal centers. The study was approved by the Ethics Committee of Ghent University Hospital
(Reference number: B670201317826) and the Royal Free Hospital (Reference number: 13/LO/0729).
The patient cohorts are described in Figure 1. The first cohort consisted of HIV-1 seroconverters
on long-term ART initiated and uninterrupted since PHI (SRCV on ART; n = 25). These patients were
selected on the basis of the following inclusion criteria: (a) ART for 4 years; (b) long-term aviremia
(<50 HIV-1 RNA copies (c)/ml); and (c) an absence of treatment failure defined by a viral load (VL)
400 HIV-1 RNA c/ml. Seroconversion to HIV-1 was defined by: (a) negative HIV-1 antibody by
enzyme-linked immunosorbent assay (ELISA) and evidence of HIV-1 viremia 5000 HIV-1 RNA c/ml
plasma and/or (b) incomplete HIV-1 Western blot with 3 bands and/or a detuned assay with a value
of 0.6 for HIV-1 clade B patients.
The second cohort of LTNPs (n = 17) were therapy-naı¨ve patients, with 7 years of documented
HIV-1 infection, viremia 1000 HIV-1 c/ml and a CD4 T cell count 500 cells/mm3 during follow-up.
Exception was made for temporary ART to prevent mother-to-child transmission.
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The third cohort consisted of HIV-1 infected patients successfully treated by ART initiated during
chronic infection (Chronic ART; n = 32) with: (a) a treatment duration of 4 years and (b) long-term
undetectable VL (<50 HIV-1 c/ml for 4 years). ART failure during follow-up was defined by a VL
400 HIV-1 c/ml.
The fourth cohort consisted of recent ART-naı¨ve seroconverters (Recent SRCV; n = 10). Criteria
for the diagnosis of seroconversion and enrollment into the study were the following: (a) negative or
indeterminate HIV-1 antibody result by fourth generation ELISA and evidence of HIV-1 viremia
5000 HIV-1 c/ml plasma and/or (b) positive HIV-1 by fourth generation ELISA and two negative
confirmatory tests (negative Vidas and Immunocomb) and/or (c) positive HIV-1 by fourth generation
ELISA and negative InnoLIA.
Baseline characteristics, clinical and laboratory parameters including total duration of ART, VL
zenith, CD4 T cell count at blood sampling and nadir, as well as CD4/CD8 ratio at blood sampling
were collected and are summarized in Table 1.
Both the SRCV on ART and Chronic ART cohorts had a comparable uninterrupted ART duration
with a median of 10.8 (IQR: 4.2–11.9) and 9.8 years (4.9–14.7), (p = 0.936), respectively.
Blood and rectal biopsies
PBMCs and rectal biopsies were collected on one occasion for each patient (Figure 1). Blood was
drawn in 6 EDTA 9 ml tubes and 10 rectal biopsies were sampled after obtaining written informed
consent from the patients.
PBMCs were isolated within 4 hr of blood sampling by using Lymphoprep centrifugation (ELITech
Group, Zottegem, Belgium). Cells were manually counted using a hemocytometer counting grid, ali-
quoted in 106PBMCs as dry pellets or in fetal calf serum + 7.5% dimethyl sulfoxide and stored at
 80˚C. Flexible sigmoidoscopy was performed and 10 gut biopsies (volume around 1 mm3 of each
biopt) were taken from the mucosa of the upper rectum (10 cm from the anal margin) using single-
use biopsy forceps. Intact rectal biopsies were immediately frozen and stored at  80˚C until further
processing.
PBMCs were collected from all patients (n = 84) included in the study and rectal biopsies
were obtained from 51 patients, 14 in SRCV on ART, 8 in LTNP, and 29 in Chronic ART cohorts.
Quantification of the HIV-1 reservoir, ongoing replication and
transcription
Methods used to quantify virological parameters relating to HIV-1 reservoirs, ongoing replication,
and transcription in this study have been recently published and include total HIV-1 DNA and 2-LTR
circles (Malatinkova et al., 2014), cell-associated HIV-1 usRNA (Kiselinova et al., 2014) with the
use of droplet digital PCR (ddPCR) and integrated HIV-1 DNA measured by a repetitive sampling
Alu-HIV PCR (Liszewski et al., 2009; De Spiegelaere et al., 2014).
Total HIV-1 DNA, 2-LTR circles, and HIV-1 usRNA were measured in triplicates on ddPCR with the
QX100Droplet Digital PCR platform (Bio-Rad, Hercules, CA). The ddPCR mix was made by adding 2
ml of sample (restricted genomic DNA [gDNA] or plasmid DNA) or 4 ml of sample (cDNA) to 10 ml 2
ddPCRÔ supermix for probes (Bio-Rad), 500 nM of primers and 250 nM of probe in a final volume
of 20 ml. ddPCR amplification reactions consisted of initial denaturation at 95˚C for 5 min, followed
by 40 cycles of 95˚C for 30 s denaturation and assay-specific annealing/elongation temperature
(Supplementary file 1) for 60 s with a ramp rate of 2.5˚C/s. Droplets were read by the QX100 drop-
let reader (Bio-Rad) and the data was analyzed with the QuantaSoft analysis software (Bio-Rad). Pri-
mers and probes used for each quantification assay are summarized in Supplementary file 1 and
were purchased from IDT DNA Technologies (Integrated DNA Technologies, Leuven, Belgium).
Total and integrated HIV-1 DNA
Total gDNA was isolated from 106 PBMCs using DNeasy Blood & Tissue Kit (Qiagen, Venlo, The
Netherlands) and eluted in 75 ml elution buffer, kept at 56˚C for 10 min in order to maximize
the DNA yield.
Three intact rectal biopsies were pooled per patient and used to isolate gDNA using DNeasy
Blood & Tissue Kit (Qiagen). Total gDNA was eluted in 40 ml elution buffer to concentrate the sam-
ple and kept at 56˚C for 10 min.
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To measure total HIV-1 DNA, an enzyme restriction digestion with EcoRI (Promega, Leiden, The
Netherlands) was performed on gDNA from both PBMCs and rectal biopsies with the use of 17.3 ml
gDNA in a total volume of 20 ml of restriction mix. This step is preferred for ddPCR as the fragmented
DNA will be more uniformly distributed in all droplets compared to full-length chromosomal DNA.
To quantify integrated HIV-1 DNA, gDNA isolated from PBMCs was subjected to a repetitive sam-
pling Alu-HIV PCR, according to a recently described protocol (De Spiegelaere et al., 2014). Briefly, a
method based on Poisson statistics was used to analyze the binomial data of positive and negative
reactions from a 40-replicate Alu-HIV PCR (De Spiegelaere et al., 2014). First, total HIV-1 DNA was
measured in gDNA samples by ddPCR and based on these measures, each sample was diluted to
approximately five copies of total HIV-1 DNA per PCR replicate and distributed in replicates. Alu-HIV
PCR has been described previously (Liszewski et al., 2009; Yu et al., 2008; De Spiegelaere et al.,
2014) and was performed by using an HIV-1-specific reverse primer in Gag and a human Alu-specific
forward primer (Supplementary file 1) in 40 replicates. In parallel, 20 replicates were run for back-
ground quantification by using only the HIV-1 Gag primer. The PCR mix was made by adding 10 ml of
diluted gDNA sample to 10 ml PCR mix consisting of 5Go Taq G2 master mix, 0.2 ml Go Taq G2 DNA
Polymerase, 4 mM of dNTP mix (Promega), 200 nM of Alu primer and 1200 nM of HIV-1 primer in a
final volume of 20 ml. PCR amplification reactions consisted of initial denaturation at 95˚C for 2 min, fol-
lowed by 40 cycles of 95˚C for 15 s denaturation, 50˚C for 15 s annealing, and 70˚C for 3.5 min elonga-
tion. 2 ml of the PCR product were processed in the nested qPCR (Light Cycler 480 System, Roche
Applied Science, Penzberg, Germany), qPCR mix contained 2 LightCycler 480 Probes Master mix
(Roche Applied Science, Vilvoorde, Belgium), 400 nM primers, and 200 nM probe
(Supplementary file 1), and qPCR consisted of initial denaturation at 95˚C for 5 min, followed by 45
cycles of 95˚C for 15 s denaturation, and 60˚C for 1 min annealing/elongation.
The quantities of total and integrated HIV-1 DNA c/106 PBMCs or total HIV-1 DNA c/106 cells in
rectal biopsies were normalized to a reference gene RPP30 measured by ddPCR. The number of
cells assayed per patient was measured by RPP30 in all PBMCs and rectal biopsies samples.
Episomal HIV-1 2-LTR circles
Episomal HIV-1 2-LTR circles were measured in plasmid DNA isolated by QIAprep Spin Miniprep kit
(Qiagen) from dry pelleted 106 PBMCs. A known number of pSIF1-H1-Puro non-HIV plasmid was
spiked to the samples (System Biosciences, Mountain view, CA) as an internal control for copy num-
ber normalization and plasmid DNA was eluted in 25 ml in order to increase DNA concentration, as
described previously (Malatinkova et al., 2014). The internal reference plasmid was quantified by
detection of the woodchuck hepatitis virus posttranscriptional regulatory element (WPRE)
(Lizee et al., 2003). The 2-LTR assay is designed to span over the 2-LTR junction (Buzon et al.,
2010; Supplementary file 1).
Cell-associated HIV-1 usRNA
RNA was isolated from 106 PBMCs by using RNeasy mini kit (Qiagen) subjected to DNase treatment
by RNase-Free DNase Set (Qiagen) and eluted in 30 ml nuclease-free water. Samples were measured
by NanoDrop 2000 (Thermo Fisher Scientific, Waltham, MA) and 1.5 mg of RNA was processed by
the iScript cDNA Synthesis Kit (Bio-Rad) 5 min at 25˚C, 30 min at 42˚C, and 5 min at 85˚C. The cDNA
was used to measure HIV-1 usRNA on ddPCR.
Normalization of input cDNA was performed by quantifying gene expression of stably expressed
internal reference genes as described earlier (Ceelen et al., 2014; Messiaen et al., 2012). Briefly,
the three most stably expressed reference genes (from total of nine genes tested) were selected
over all patient samples by geNorm analysis (Beta-2-microglobulin: B2M, TATA box binding
protein: TBP, and Ubiquitin C: UBC) (Vandesompele et al., 2002). Normalization factors were deter-
mined per patient as the geometric mean of the three most stable reference genes. Subsequently,
raw ddPCR values for HIV-1 usRNA were divided by the normalization factors to reach normalized
data and reported as c/106 PBMCs for each patient sample. Previously described primers and probe
sets for HIV-1 usRNA quantification were used (Kiselinova et al., 2014; Palmer et al., 2008), as
summarized in Supplementary file 1.
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Statistical analysis
Total HIV-1 DNA, integrated HIV-1 DNA, 2-LTR circles and cell-associated HIV-1 usRNA levels as
well as immunological data (CD4/CD8 T cell ratios and CD4 T cell counts at sampling and nadir CD4
T cell counts) were described using median values and IQR. Statistical analysis was performed using
R (RStudio, Inc., Boston, MA). Standard non-parametric test (Wilcoxon Signed Rank Test) was per-
formed to assess statistically significant differences between patient cohorts. A p-value of <0.05 was
considered significant. Linear regression was used to assess the correlations.
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